Action

EGFR

Approval Jurisdiction

2013 FDA 2013 EMA

Approved for clinical use

NSCLC with EGFR mutations

Brutto

CAS

850140-72-6

Commercial Vendor

Boehringer Ingelheim

Compound Image

Afatinib.png

Compound name

Afatinib

InChI

InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1

InChI Key

ULXXDDBFHOBEHA-CWDCEQMOSA-N

MW

485.90

PubChem CID

10184653

Reference

Reference 2

SMILES

CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4

Approved Drug List

1